Mark C. Schneyer - Jun 8, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, Chief Financial Officer
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Jun 8, 2023
Transactions value $
-$24,369
Form type
4
Date filed
6/12/2023, 08:48 PM
Previous filing
May 19, 2023
Next filing
Aug 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +1.89K +8.64% $0.00 23.8K Jun 8, 2023 Direct
transaction ACAD Common Stock Sale -$24.4K -974 -4.09% $25.02 22.8K Jun 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.89K -50% $0.00 1.89K Jun 8, 2023 Common Stock 1.89K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
F3 The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.